In vitro and in vivo evaluation of the effects of aluminum [18F]fluoride radiolabeling on an integrin αvβ6-specific peptide

被引:32
|
作者
Hausner, Sven H. [1 ,2 ]
Bauer, Nadine [1 ]
Sutcliffe, Julie L. [1 ,2 ,3 ]
机构
[1] Univ Calif Davis, Dept Biomed Engn, Davis, CA 95616 USA
[2] Univ Calif Davis, Dept Internal Med, Div Hematol Oncol, Sacramento, CA 95817 USA
[3] Univ Calif Davis, Ctr Mol & Genom Imaging, Davis, CA 95616 USA
基金
美国能源部;
关键词
Fluorine; 18; Aluminum [18F]fluoride; NOTA; Peptide; Integrin; Positron emission tomography; POSITRON-EMISSION-TOMOGRAPHY; ALPHA-V-BETA-6; INTEGRIN; CELL CARCINOMA; OVARIAN-CANCER; BREAST-CANCER; LUNG-CANCER; PET; INTEGRIN-ALPHA(V)BETA(6); EXPRESSION; RECEPTOR;
D O I
10.1016/j.nucmedbio.2013.09.009
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Introduction: Incorporation of fluorine-18 (F-18) into radiotracers by capturing ionic [F-18]-species can greatly accelerate and simplify radiolabeling for this important positron emission tomography (PET) radioisotope. Among the different strategies, the incorporation of aluminum [F-18]fluoride (Al[F-18](2+)) into NOTA chelators has recently emerged as a robust approach to peptide radiolabeling. This study presents Al[F-18](2+) -radiolabeling of an alpha(v)beta(6) integrin-targeted peptide (NOTA-PEG(28)-A20FMDV2) and its in vitro and in vivo evaluation. Methods: Aluminum [F-18]fluoride was prepared at r.t. from [F-18]fluoride (40 MBq-11 GBq) and introduced into NOTA-PEG(28)-A20FMDV2 (1) in sodium acetate (pH 4.1; 100 degrees C, 15 min). The radiotracer Al[F-18] NOTA-PEG(28)-A20FMDV2 (2) was purified by HPLC, formulated in PBS and evaluated in vitro (stability; binding and internalization in alpha(v)beta(6)(+) and alpha(v)beta(6)(-) cells) and in vivo (paired alpha(v)beta(6)(+) and alpha(v)beta(6)(xenograft mice: PET/CT, biodistribution, tumor autoradiography and metabolites). Results: The radiotracer 2 was prepared in 90 +/- 6 mm (incl. formulation; n = 3) in 19.3 +/- 5.4% decay corrected radiochemical yield (radiochemical purity: >99%; specific activity: 158 +/- 36 GBq/mu mol) and was stable in PBS and serum (2 h). During in vitro cell binding studies, 2 showed high, alpha(v)beta(6)-targeted binding (alpha(v)beta(6)(+): 42.4 +/- 1.2% of total radioactivity, ratio (+)/(-) = 8.4/1) and internalization (alpha(v)beta(6)(+): 28.3 +/- 0.5% of total radioactivity, (+)/(-) = 11.7/1). In vivo, 2 maintained alpha(v)beta(6)-targeted binding (biodistribution; 1 h: 04,138(+): 1.74 +/- 038% ID/g, (+)/(-) = 2.72/1; 4 h: alpha(v)beta(6)(+): 1.21 0.56% ID/g, (+)/(-) = 4.0/1; 11% intact 2 in tumor at 1 h), with highest uptake around the tumor edge (autoradiography). Most of the radioactivity cleared rapidly in the urine within one hour, but a significant fraction remained trapped in the kidneys (4 h: 229 44% ID/g). Conclusion: The Al[F-18]/NOTA-based radiolabeling was rapid and efficient, and the radiotracer 2 showed good alpha(v)beta(6)-selectivity in vitro and in vivo. However, in contrast to A20FMDV2 labeled with covalently bound [F-18]-prosthetic groups (e.g., [F-18]fluorobenzoic acid), 2 demonstrated significant trapping in kidneys, similar to radiometal-labeled chelator-analogs of 2. (C) 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码:43 / 50
页数:8
相关论文
共 50 条
  • [41] Synthesis, radiolabeling and preliminary in vivo evaluation of [18F]FE-PE2I, a new probe for the dopamine transporter
    Schou, Magnus
    Steiger, Carsten
    Varrone, Andrea
    Guilloteau, Denis
    Halldin, Christer
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (16) : 4843 - 4845
  • [42] In vitro and in vivo evaluation of a technetium-99m-labeled cyclic RGD peptide as a specific marker of αVβ3 integrin for tumor imaging
    Su, Z
    Liu, GZ
    Gupta, S
    Zhu, ZH
    Rusckowski, M
    Hnatowich, DJ
    BIOCONJUGATE CHEMISTRY, 2002, 13 (03) : 561 - 570
  • [43] [18F]Fluciclatide in the in vivo evaluation of human melanoma and renal tumors expressing αvβ3 and αvβ5 integrins
    Esther Mena
    Rikard Owenius
    Baris Turkbey
    Richard Sherry
    Gennady Bratslavsky
    Sven Macholl
    Matthew P. Miller
    Ed J. Somer
    Liza Lindenberg
    Stephen Adler
    Joanna Shih
    Peter Choyke
    Karen Kurdziel
    European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41 : 1879 - 1888
  • [44] [18F]Fluciclatide in the in vivo evaluation of human melanoma and renal tumors expressing αvβ3 and αvβ5 integrins
    Mena, Esther
    Owenius, Rikard
    Turkbey, Baris
    Sherry, Richard
    Bratslavsky, Gennady
    Macholl, Sven
    Miller, Matthew P.
    Somer, Ed J.
    Lindenberg, Liza
    Adler, Stephen
    Shih, Joanna
    Choyke, Peter
    Kurdziel, Karen
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 (10) : 1879 - 1888
  • [45] Synthesis and in Vitro and in Vivo Evaluation of [18F]FDG-Labeled Folates: Potential PET Radiopharmaceuticals
    Aljammaz, I. J.
    Al-Otaibi, B.
    Amer, S.
    Okarvi, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 : S183 - S183
  • [46] Synthesis, in vitro and in vivo evaluation of [18F]fluoronorimatinib as a novel radiotracer for imaging of gastrointestinal stromal tumors
    Prause, Martin
    Niedermoser, Sabrina
    Riester, Stephanie
    Suhr, Anne-Maria
    Consolino, Lorena
    Taguchi, Takahiro
    Decristoforo, Clemens
    Waengler, Bjoern
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2017, 60 : S107 - S107
  • [47] In vitro and in vivo evaluation of doxorubicin conjugates with the bicyclic peptide c(RGDfK)2 that target integrin αvβ3
    Ryppa, Claudia
    Mann-Steinberg, Hagit
    Fichtner, Iduna
    Weber, Holger
    Satchi-Fainaro, Ronith
    Kratz, Felix
    CANCER RESEARCH, 2008, 68 (09)
  • [48] First-in-human studies of [18F]αvβ6-BP, a PET imaging probe targeting the cancer-associated integrin αvβ6
    Hausner, Sven
    Davis, Ryan
    Bold, Richard
    Chew, Helen
    Daly, Megan
    Foster, Cameron
    Kim, Edward
    Sutcliffe, Julie
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59
  • [49] Comment on "In vitro and in vivo evaluation of a technetium-99m-labeled cyclic RGD peptide as a specific marker of αvβ3 integrin for tumor imaging"
    Haubner, R
    Weber, W
    BIOCONJUGATE CHEMISTRY, 2003, 14 (02) : 274 - 274
  • [50] SYNTHESIS, RADIOLABELING AND IN VIVO EVALUATION OF S-AND R- N-Me [18F]FAMP AS PET TUMOR IMAGING CANDIDATES
    Yu, W.
    Williams, L.
    Malveaux, E.
    Camp, V. M.
    Zhang, Z.
    Goodman, M. M.
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2005, 48 : S34 - S34